These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 12388602

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis.
    Guillot TS, Shepherd KR, Richardson JR, Wang MZ, Li Y, Emson PC, Miller GW.
    J Neurochem; 2008 Sep; 106(5):2205-17. PubMed ID: 18643795
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice.
    Patel J, Mooslehner KA, Chan PM, Emson PC, Stamford JA.
    J Neurochem; 2003 May; 85(4):898-910. PubMed ID: 12716422
    [Abstract] [Full Text] [Related]

  • 5. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice.
    Fumagalli F, Gainetdinov RR, Wang YM, Valenzano KJ, Miller GW, Caron MG.
    J Neurosci; 1999 Apr 01; 19(7):2424-31. PubMed ID: 10087057
    [Abstract] [Full Text] [Related]

  • 6. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.
    Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR, Fleckenstein AE.
    J Pharmacol Exp Ther; 2002 Mar 01; 300(3):1093-100. PubMed ID: 11861820
    [Abstract] [Full Text] [Related]

  • 7. Effect of the weaver mutation on the expression of dopamine membrane transporter, tyrosine hydroxylase and vesicular monoamine transporter in dopaminergic neurons of the substantia nigra and the ventral tegmental area.
    Adelbrecht C, Agid Y, Raisman-Vozari R.
    Brain Res Mol Brain Res; 1996 Dec 31; 43(1-2):291-300. PubMed ID: 9037545
    [Abstract] [Full Text] [Related]

  • 8. Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity.
    Xie T, McCann UD, Kim S, Yuan J, Ricaurte GA.
    J Neurosci; 2000 Oct 15; 20(20):7838-45. PubMed ID: 11027249
    [Abstract] [Full Text] [Related]

  • 9. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons.
    Liang CL, Nelson O, Yazdani U, Pasbakhsh P, German DC.
    J Comp Neurol; 2004 May 17; 473(1):97-106. PubMed ID: 15067721
    [Abstract] [Full Text] [Related]

  • 10. Deletion of VGLUT2 in midbrain dopamine neurons attenuates dopamine and glutamate responses to methamphetamine in mice.
    Shen H, Chen K, Marino RAM, McDevitt RA, Xi ZX.
    Pharmacol Biochem Behav; 2021 Mar 17; 202():173104. PubMed ID: 33444596
    [Abstract] [Full Text] [Related]

  • 11. Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system.
    Wilhelm CJ, Johnson RA, Lysko PG, Eshleman AJ, Janowsky A.
    J Pharmacol Exp Ther; 2004 Sep 17; 310(3):1142-51. PubMed ID: 15102929
    [Abstract] [Full Text] [Related]

  • 12. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium.
    Staal RG, Hogan KA, Liang CL, German DC, Sonsalla PK.
    J Pharmacol Exp Ther; 2000 May 17; 293(2):329-35. PubMed ID: 10772999
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Methamphetamine-induced alterations in dopamine transporter function.
    Bennett BA, Hollingsworth CK, Martin RS, Harp JJ.
    Brain Res; 1998 Jan 26; 782(1-2):219-27. PubMed ID: 9519266
    [Abstract] [Full Text] [Related]

  • 15. Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine.
    Nirenberg MJ, Chan J, Liu Y, Edwards RH, Pickel VM.
    J Neurosci; 1996 Jul 01; 16(13):4135-45. PubMed ID: 8753875
    [Abstract] [Full Text] [Related]

  • 16. Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity.
    Guilarte TR, Nihei MK, McGlothan JL, Howard AS.
    Neuroscience; 2003 Jul 01; 122(2):499-513. PubMed ID: 14614914
    [Abstract] [Full Text] [Related]

  • 17. Changes in gene expression linked to methamphetamine-induced dopaminergic neurotoxicity.
    Xie T, Tong L, Barrett T, Yuan J, Hatzidimitriou G, McCann UD, Becker KG, Donovan DM, Ricaurte GA.
    J Neurosci; 2002 Jan 01; 22(1):274-83. PubMed ID: 11756511
    [Abstract] [Full Text] [Related]

  • 18. L-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice.
    Reveron ME, Savelieva KV, Tillerson JL, McCormack AL, Di Monte DA, Miller GW.
    Neurotoxicology; 2002 Oct 01; 23(4-5):611-9. PubMed ID: 12428733
    [Abstract] [Full Text] [Related]

  • 19. Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone-formation-related molecules.
    Miyazaki I, Asanuma M, Diaz-Corrales FJ, Fukuda M, Kitaichi K, Miyoshi K, Ogawa N.
    FASEB J; 2006 Mar 01; 20(3):571-3. PubMed ID: 16403784
    [Abstract] [Full Text] [Related]

  • 20. Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity.
    Volz TJ, Farnsworth SJ, Rowley SD, Hanson GR, Fleckenstein AE.
    Synapse; 2009 Feb 01; 63(2):147-51. PubMed ID: 19021208
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.